Gynecologic Oncology

Eighty percent of patients with early-stage dMMR solid tumors given neoadjuvant dostarlimab underwent nonoperative management of their disease.

Dostarlimab/chemotherapy was granted an expanded approval by Health Canada to treat patients with primary advanced or first recurrent endometrial cancer.

Linda R. Duska, MD, MPH, contextualizes updated OS and PFS2 findings from the second interim analysis of KEYNOTE-A18 in locally advanced cervical cancer.

Pamela T. Soliman, MD, MPH, discusses a phase 1 investigation of temsirolimus plus metformin in patients with recurrent endometrial cancer.

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.

IHC staining is top of mind for the use of ADCs in cervical cancer management; however, the specific indications for each agent must be considered.

Tisotumab vedotin was granted approval by the EU for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Christian Marth, MD, PhD, and John Chan, MD, discuss subgroup data for frontline lenvatinib/pembrolizumab in endometrial cancer after perioperative chemotherapy.

Christian Marth, MD, PhD, and John Chan, MD, discuss frontline chemoimmunotherapy combinations in advanced endometrial cancer.

Christian Marth, MD, PhD, and John Chan, MD, discuss data for frontline lenvatinib plus pembrolizumab in advanced endometrial cancer.

Ramez N. Eskander, MD, discusses the key efficacy findings and future implications of the NIVEC trial of nivolumab in resectable dMMR endometrial cancer.

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.

Christian Marth, MD, PhD, and John Chan, MD, discuss frontline treatment trends and challenges in advanced endometrial cancer.

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends in gynecologic cancer care discussed during the 2025 SGO Annual Meeting.

Treatment with abemaciclib plus hormonal therapy showed promise in LGSOC/EEC but not in HGSOC, and larger studies are needed to validate these findings.

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Taliya Lantsman, MD, discusses real-world safety and efficacy data with dostarlimab plus chemotherapy in patients with advanced endometrial cancer.

Maintenance selinexor improved progression-free survival in TP53 wild-type advanced endometrial cancer.

Dostarlimab plus chemotherapy improved 24-month DOR rates vs placebo plus chemotherapy in patients with primary advanced or recurrent endometrial cancer.

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Shannon Westin, MD, MPH, FACOG, discusses the efficacy of durvalumab plus chemotherapy and olaparib in pMMR recurrent endometrial cancer.